Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer typesDavid R. Gandara, Ryon P. Graf, Lilia Bouzit et al.|Journal for ImmunoTherapy of Cancer|2025Cited by 48
Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patientsJúlia C.F. Quintanilha, Federico Innocenti, Jin Wang et al.|British Journal of Cancer|2021Cited by 24
Genome‐wide association studies of survival in 1520 cancer patients treated with bevacizumab‐containing regimensJúlia C.F. Quintanilha, Federico Innocenti, Jin Wang et al.|International Journal of Cancer|2021Cited by 10
Bevacizumab-induced hypertension and proteinuria: A genome-wide analysis of more than 1,000 patientsF. Innocenti, Júlia C.F. Quintanilha, Jian Wang et al.|European Journal of Cancer|2020Cited by 2
Correction: Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patientsJúlia C.F. Quintanilha, Federico Innocenti, Jin Wang et al.|British Journal of Cancer|2021Cited by 1